SYNACT (SYNACT) News
Follow SYNACT (SYNACT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
SYNACT - SynAct Pharma to Participate in Investor and Partnering Conferences
SYNACT - SynAct Pharma to Participate in Investor and Partnering Conferences
NEWS | Sep 22, 2026, 05:30 AM UTC
M
WHO review in Lancet Microbe lists SynAct’s resomelagon candidate therapy
A WHO review published in Lancet Microbe names SynAct Pharma’s resomelagon as one of six dengue therapeutic candidates, citing evidence for further clinical development.
MACRO | Sep 17, 2026, 02:11 PM UTC
L
SYNACT - WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development
SYNACT - WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development
NEWS | Sep 16, 2026, 09:55 AM UTC
L
WHO names Resomelagon among key dengue drug candidates
SynAct Pharma AB OMXSTO:SYNACT is mentioned in a TradingView News item stating the WHO named Resomelagon among key dengue drug candidates.
MACRO | Sep 16, 2026, 09:49 AM UTC
M
WHO names SynAct Pharma oral resomelagon among six dengue candidates
WHO listed SynAct’s oral therapy resomelagon as one of six dengue drug candidates with supporting efficacy data for further clinical development, per a Lancet Microbe review. SynAct expects Phase 2 RESOVIR-2 results from
EQUITY | Sep 16, 2026, 09:35 AM UTC
L
SynAct Pharma to Present at Investing in Life Science on September 22
The 4th edition of Investing in Life Science takes place on September 22 in Stockholm. Jeppe Øvlesen, CEO will present SynAct Pharma to specialist life science investors and potential strategic partners.Investing in Life
EQUITY | Sep 10, 2026, 07:01 AM UTC
M
SynAct Pharma prepares phase III trial discussion with FDA
SynAct Pharma presented post-hoc analysis of its phase IIb ADVANCE rheumatoid arthritis study using resomelagon, addressing placebo responses and reinforcing its therapeutic profile. The company is preparing to discuss p
REGULATION | Sep 07, 2026, 02:30 PM UTC
M
SynAct post-hoc Phase 2b analysis backs Phase 3 path
SynAct Pharma AB says a post-hoc analysis of its Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development. FDA trial-design discussions are planned for Q4 2026.
REGULATION | Sep 07, 2026, 09:15 AM UTC
L
SynAct Pharma says advance analysis supports Phase 3 development
SynAct Pharma says advance analysis supports its Phase 3 development.
EQUITY | Sep 07, 2026, 09:14 AM UTC
L
SynAct Pharma CEO and CSO sell shares
SynAct Pharma CEO and CSO sold shares, per TradingView News.
EQUITY | Sep 03, 2026, 05:33 AM UTC
L
SynAct Pharma to present resomelagon preclinical RA data in 2026
SynAct Pharma will present new resomelagon preclinical data on a Phase 3-ready RA therapeutic candidate at the 17th World Congress of Inflammation 2026.
GEOPOLITICS | Aug 28, 2026, 09:45 AM UTC